Skip to main content
TipRanks
Go Ultimate75% OFF

BioStem Technologies (BSEM) AI Stock Analysis

315 Followers
BSEM

BioStem Technologies

(NASDAQ:BSEM)

Select Model
Rating:44Neutral
Price Target:$0.91â–¼(-2.99% Downside)
Action:reiterated
Date:11/14/26

The score is held down primarily by weak and volatile financial performance (TTM losses and cash burn) and bearish technicals (price well below key moving averages with negative MACD). Valuation provides limited support due to a negative P/E, while the earnings call adds only partial offset on improved revenue guidance and planned cost/margin initiatives amid significant near-term liquidity and execution risk.

Positive Factors
Multi-product adoption and GPO accessBroader adoption across product lines can deepen customer relationships, increase revenue per account, and make the commercial platform more productive. This expansion, combined with GPO access, supports more durable hospital-channel growth and strengthens distribution over the next several quarters.
Negative Factors
Severe cash burn and liquidity pressureRapid cash depletion and increasing operating cash use indicate that the business is not currently funding itself. Persistently negative cash generation could force additional financing or asset actions, limiting strategic flexibility and increasing execution risk over the next several quarters.

BioStem Technologies (BSEM) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%BSEM-75.71%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$17.93M
Dividend Yield
―
Average Volume (3M)
187.93K
Price to Earnings (P/E)
-0.4
Beta (1Y)
1.88
Revenue Growth
-86.50%
EPS Growth
-291.62%
Country
US
Employees
73
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

BioStem Technologies Business Overview & Revenue Model

Company Description

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used...

BioStem Technologies Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-28.08%|Next Earnings Date:May 24, 2021
Earnings Call SentimentNeutral

The call presented meaningful operational and commercial progress, including hospital revenue growth, stronger multi-product adoption, expanded GPO access, completed systems integration, raised 2026 revenue guidance and planned cost and manufacturing initiatives. However, these positives were balanced by declining total revenue, lower gross margins, higher operating expenses, a widening net and adjusted EBITDA loss, reduced cash, increased operating cash use and an outstanding BioTissue payment. The overall tone was cautiously optimistic about the 2027 plan but acknowledged substantial near-term financial and liquidity challenges.

Positive Updates

Sequential Hospital Revenue Growth
Hospital revenue increased sequentially to $6.8 million from $6.7 million in the prior quarter, representing 2% sequential growth. July and September were described as the strongest hospital sales months since the acquisition.

Negative Updates

Total Revenue Declined Sequentially
Third-quarter revenue totaled $7.6 million compared with $7.9 million in the second quarter. Physician office revenue declined to $810,000 from $1.1 million, and management expects minimal contributions from the physician office channel going forward.

Company Guidance

BioStem continues to expect sequential growth in the fourth quarter, with minimal contributions from the physician office channel, and raised its full year 2026 revenue guidance to $28 million to $29 million from the previous range of $26 million to $29 million; in 2027, operating expenses are expected to decline substantially and the adjusted EBITDA loss to narrow across 2027, while the cost reduction plan is expected to lower annualized cash operating expenses by approximately $10 million to $12 million, with the full benefit beginning in the first quarter of 2027. The company expects to complete the Neox and Clarix technology transfer and begin in-house production in the first half of 2027, subject to process validation and applicable regulatory requirements; margins are expected to remain in the 50s until then, and management said it feels it can get into the 70s, with a 10 to 15-point improvement in gross margin over time.

BioStem Technologies Financial Statement Overview

Summary

Fundamentals are pressured by a sharp swing to deep losses and cash burn in TTM, with negative profitability and negative operating/free cash flow signaling rising funding needs. The balance sheet is comparatively better (manageable leverage and positive equity), but the deterioration from strong 2024 results to weak TTM raises durability and liquidity concerns.

Income Statement

22Negative

Balance Sheet

56Neutral

Cash Flow

33Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue-63.14M47.48M301.83M16.69M6.88M4.34M
Gross Profit-73.61M44.22M288.08M15.42M5.99M2.87M
EBITDA-34.04M-308.13K31.49M-7.55M-6.54M-602.11K
Net Income-40.43M-6.58M31.88M-8.48M-7.19M-1.45M
Balance Sheet
Total Assets43.58M50.03M140.38M14.56M3.47M2.67M
Cash, Cash Equivalents and Short-Term Investments971.14K29.55M22.83M239.41K772.14K340.33K
Total Debt1.17M3.33M4.39M4.72M5.09M4.83M
Total Liabilities25.25M10.89M99.50M15.90M7.42M8.47M
Stockholders Equity18.33M39.14M40.88M-1.34M-4.08M-5.96M
Cash Flow
Free Cash Flow-12.85M6.59M24.05M-3.71M-165.91K-152.29K
Operating Cash Flow-12.36M9.94M24.48M-3.50M303.57K-109.44K
Investing Cash Flow-15.68M-2.10M-1.68M-210.33K-469.48K-7,848
Financing Cash Flow1.85M-1.12M-206.78K3.18M597.71K357.42K

BioStem Technologies Technical Analysis

Technical Analysis SentimentNegative
Last Price0.94

Price Trends

50DMA2.47Negative
100DMA3.02Negative
200DMA3.91Negative

Market Momentum

MACD-0.36Negative
RSI31.65Neutral
STOCH12.23Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSEM, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 1.27, below the 50-day MA of 2.47, and below the 200-day MA of 3.91, indicating a bearish trend. The MACD of -0.36 indicates Negative momentum. The RSI at 31.65 is Neutral, neither overbought nor oversold. The STOCH value of 12.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSEM.

BioStem Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BSEM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NCELNCEL48Neutral$14.43M8.1221.75%―――
CELUCELU47Neutral$18.53M-0.32142.25%―-58.14%47.25%
JSPRJSPR46Neutral$11.47M-0.3739.72%――16.44%
LGVNLGVN45Neutral$6.71M-0.26-243.26%―-18.93%39.19%
BSEMBSEM44Neutral$17.93M-0.40-138.28%―-86.50%-291.62%
PLURPLUR27Underperform$14.09M-0.36147.42%―10.03%13.85%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%BSEMPLURCELUJSPRNCELLGVNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BSEM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BSEMBioStem Technologies 0.94-2.81-75.07%
PLURPluri Inc.0.98-2.58-72.47%
CELUCelularity Inc.0.57-1.12-66.21%
JSPRJasper Therapeutics, Inc.10.34-45.16-81.37%
NCELNewcelx Ltd.2.68-0.63-19.03%
LGVNLongeveron Inc.2.11-4.04-65.67%

BioStem Technologies Corporate Events

Business Operations and StrategyPrivate Placements and Financing

BioStem Technologies Completes $3 Million Private Placement Financing

Negative
Sep 30, 2026

On September 29–30, 2026, BioStem Technologies raised approximately $3 million in a private placement, selling 735,296 shares of common stock at $4.08 per share along with Series A and Series B warrants for an equal number of shares, each carrying a...

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance

BioStem Secures $40 Million Equity Financing Facility

Positive
Sep 18, 2026

On September 18, 2026, BioStem Technologies entered into a $40 million committed equity facility with Roth Principal Investments, giving the company the right, but not the obligation, to sell up to 12,050,000 registered common shares over a 36‑month...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026